

Curriculum Vitae

Personal information **Daiana Vasilcanu**

Work experience

1. Employer: Craiova University Hospital no1
 - Start date: 101996
 - End date: 102001
 - Position: resident in diabetologi
 - Activities:
 - Country: Romania
2. Employer: Craiova University Hospital
 - Start date: 102001
 - End date: 012002
 - Position: specialist in diabetologi
 - Activities:
 - Country: Romania
3. Employer: Karolinska Institute
 - Start date: 012002
 - End date: 022006
 - Position: PhD student
 - Activities: Full time PhD student in Oncologi_Pathology, Cytology and Experimental Pathology at Cancer Centrum Karolinska, Karolinska Institute
 - Country: Sweden
4. Employer: Karolinska Institute
 - Start date: 022006
 - End date: 102008
 - Position: Postdoc
 - Activities: Cytology and Experimental Pathology at Cancer Centrum Karolinska, Karolinska Institute
 - Country: Sweden
5. Employer: Karolinska University Hospital
 - Start date: 102008
 - End date: 122013
 - Position: residency in oncology
 - Activities: resident in general oncology
 - Country: Sweden
6. Employer: Karolinska University Hospital
 - Start date: 012014
 - End date: 022015
 - Position: specialist in oncology
 - Activities: Thyroid cancer, head_neck cancers
 - Country: Sweden
7. Employer: Medical Product Agency Sweden
 - Start date: 032015
 - End date: 102017
 - Position: clinical assessor
 - Activities: Pharmacovigilance Department
 - Country: Sweden
8. Employer: Medical Product Agency Sweden
 - Start date: 112017
 - End date:
 - Position: clinical assessor
 - Activities: Efficacy and Safety Department, Oncology group. Clinical assessor for the Rapporteur in MAA procedures for Avastin_biosimilars, extension of indications for Imbruvica, Talzena (prostate cancer_ ongoing), Abecma (pharmacovigilance), Uxil (Dasatinib hybrid_pharmacovigilance); Type II variations updates with final safety or efficacy data from pivotal studies, data from PASS.
 - Country: Sweden
9. Employer: S:t Göran Hospital_Prostate Cancer Centrum
 - Start date: 082019
 - End date: 012022
 - Position: specialist oncology
 - Activities: oncologist 20% part time position, at Prostate Cancer Center, St Görans Hospital , Stockholm, Sweden; involved in diagnosis, treatment, monitoring of patients with prostate cancer
 - Country: Sweden

Education and training

1. Subject: Medicine University Craiova
 - Start date: 101989
 - End date: 091995
 - Qualification: student
 - Organisation: 6 years at Medicine University, sept 1989 Degree in Medicine and Surgery
 - Country: Romania

2. Subject: Medicine University Hospital Craiova
 - Start date: 091995
 - End date: 101996
 - Qualification: Medical doctor
 - Organisation: Fellowship in Surgery (6 months) and Internal Medicine (6 months), sept 1996 medical doctor with prescription right
 - Country: Romania
3. Subject: University Hospital Craiova
 - Start date: 101996
 - End date: 102001
 - Qualification: resident
 - Organisation: Residency in Diabetologi and Nutritional disease, 1 okt 2001_specialist in diabetes and nutritional disease
 - Country: Romania
4. Subject: Karolinska Institute
 - Start date: 012002
 - End date: 022006
 - Qualification: PhD student
 - Organisation: PhD studies in Pathology, Cytology and Experimental Pathology at Cancer Centrum Karolinska, Karolinska Institute
 - Country: Sweden
5. Subject: Karolinska University Hospital
 - Start date: 102008
 - End date: 122013
 - Qualification: resident in oncology
 - Organisation: residency in general oncology
 - Country: Sweden

Additional information

Publications

Doctoral thesis: "IGF_1R inhibition: A tool for functional studies of insulin_like growth factor family in malignant cells." Pathology, Cytology and Experimental Pathology, Karolinska Institutet, Stockholm, Sverige: http://diss.kib.ki.se/2006/91_7140_643_3/ Oct 2002; Karolinska University Press, 2006; ISBN 91_7140_643_3

Original articles: • "The cyclolignan PPP induces activation loop_specific inhibition of tyrosine phosphorylation of the insulin_like growth factor_1 receptor. Link to the phosphatidylinositol_3 kinase/Akt apoptotic pathway." Vasilcanu D, Girnita A, Girnita L, Vasilcanu R, Axelson M, Larsson O. *Oncogene*. 2004 Oct 14; 23(47):7854_62. • "Expression and growth dependency of the insulin_like growth factor I receptor in craniopharyngioma cells: a novel therapeutic approach." Ulfarsson E, Karstrom A, Yin S, Girnita A, Vasilcanu D, Thoren M, Kratz G, Hillman J, Axelson M, Larsson O, Girnita L. *Clin Cancer Res*. 2005 Jul 1;11(13):4674_80. • "The insulin_like growth factor_1 receptor inhibitor PPP produces only very limited resistance in tumor cells exposed to long_term selection." Vasilcanu D, Weng W_H, Girnita A, Lui W_O, Vasilcanu R, Axelson M, Larsson O, Larsson C, Girnita L. *Oncogene* 2006 May 25;25(22):3186_95. • "IGF_1R tyrosine kinase expression and dependency in clones of IGF_1R knockout cells (R_)." Rosengren L*, Vasilcanu D*, Vasilcanu R, Fickenscher S, Sehat B, Natalishvili N, Naughton S, Yin S, Girnita A, Girnita L, Axelson M, Larsson O. *Biochem Biophys Res Commun*. 2006 Sep 8;347(4):1059_66. Epub 2006 Jul tial therapeutic target. *Equal contribution • "β_arrestin and MDM2 mediated ubiquitination of the insulin_like growth factor_1 receptor (IGF_1R) is necessary for receptor internalization and Erk activation in IGF_1 stimulated cells." Girnita L, Shenoy S, Vasilcanu D, Girnita A, Lefkowitz RJ and Larsson O. *J Biol Chem*. 2007 Feb 15; [Epub ahead of print] • "Picropodophyllin induces downregulation of the insulin_like growth factor 1 receptor. Potential mechanistic involvement of Mdm2 and β_arrestin1." Vasilcanu R*, Vasilcanu D*, Rosengren L, Natalishvili N, Sehat B, Yin S, Girnita A, Axelson M, Girnita L and Larsson O. *Oncogene* 2007 Aug 28, [Epub ahead of print] *Equal contribution • "Inhibition of VEGF secretion and experimental choroidal neovascularization by picropodophyllin (PPP), an inhibitor of the insulin_like growth factor_1 receptor." Economou MA, Wu J, Vasilcanu D, Rosengren L, All_Ericsson C, van der Ploeg I, Menu E, Girnita L, Axelson M, Larsson O, Seregard S, Kvanta A. *Invest Ophthalmol Vis Sci*. 2008 Jun;49(6):2620_6. • "Oral picropodophyllin (PPP) is well tolerated in vivo and inhibits IGF_1R expression and growth of uveal melanoma." Economou MA, Andersson S, Vasilcanu D, All_Ericsson C, Menu E, Girnita A, Girnita L, Axelson M, Seregard S, Larsson O. *Invest Ophthalmol Vis Sci*. 2008 Jun;49(6):2337_42. • "Aberrant intracellular IGF_1R beta_subunit makes receptor knockout cells (IGF1R_/_) susceptible to oncogenic transformation." Natalishvili N, Axelson M, Girnita L, Larsson O, Vasilcanu D. *Exp Cell Res*. 2009 May 1;315(8):1458_67. Epub 2009 Jan 23. • "Over_accumulation of nuclear IGF_1 receptor in tumor cells requires elevated expression of the receptor and the SUMO_conjugating enzyme Ubc9". Denng H, Lin Y, Badin M, Vasilcanu D, Stromberg T, Jernberg_Wiklund H, Sehat B, Larsson O. *Biochem Biophys Res Commun*. 2010 Dec 11.

Projects

Memberships

Other Relevant Information